The current financial score of Bristol-Myers Squibb Co is 9.00. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 13.07B, representing a year-over-year increase of 6.93%, while its net profit experienced a year-over-year increase of 1.77%.
The current valuation score of Bristol-Myers Squibb Co is 9.12. Its current P/E ratio is 17.62, which is 42.43% below the recent high of 25.09 and 197.45% above the recent low of -17.17.
The current earnings forecast score of Bristol-Myers Squibb Co is 7.00. The average price target is 64.81, with a high of 80.00 and a low of 40.00.
The current price momentum score of Bristol-Myers Squibb Co is 3.32. Currently, the stock price is trading between the resistance level at 65.70 and the support level at 59.99, making it suitable for range-bound swing trading.
The current institutional shareholding score of Bristol-Myers Squibb Co is 7.00. The latest institutional shareholding proportion is 84.35%, representing a quarter-over-quarter decrease of 0.49%.
The current risk assessment score of Bristol-Myers Squibb Co is 9.23. The company's beta value is 0.24. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.